OBJECTIVEThe results of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort study revealed a strong association between dyslipidemia and the development of diabetic retinopathy. However, there are no experimental data on retinal fatty acid metabolism in diabetes. This study determined retinal-specific fatty acid metabolism in control and diabetic animals.RESEARCH DESIGN AND METHODSTissue gene and protein expression profiles were determined by quantitative RT-PCR and Western blot in control and streptozotocin-induced diabetic rats at 3–6 weeks of diabetes. Fatty acid profiles were assessed by reverse-phase high-performance liquid chromatography, and phospholipid analysis was performed by nano-electrospray ionization tandem mass spectrometry.RESULTSWe found a dramatic difference between retinal and liver elongase and desaturase profiles with high elongase and low desaturase gene expression in the retina compared with liver. Elovl4, an elongase expressed in the retina but not in the liver, showed the greatest expression level among retinal elongases, followed by Elovl2, Elovl1, and Elovl6. Importantly, early-stage diabetes induced a marked decrease in retinal expression levels of Elovl4, Elovl2, and Elovl6. Diabetes-induced downregulation of retinal elongases translated into a significant decrease in total retinal docosahexaenoic acid, as well as decreased incorporation of very-long-chain polyunsaturated fatty acids (PUFAs), particularly 32:6n3, into retinal phosphatidylcholine. This decrease in n3 PUFAs was coupled with inflammatory status in diabetic retina, reflected by an increase in gene expression of proinflammatory markers interleukin-6, vascular endothelial growth factor, and intercellular adhesion molecule-1.CONCLUSIONSThis is the first comprehensive study demonstrating diabetes-induced changes in retinal fatty acid metabolism. Normalization of retinal fatty acid levels by dietary means or/and modulating expression of elongases could represent a potential therapeutic target for diabetes-induced retinal inflammation.

A n automated tandem mass spectrometryebased analysis using precursor ion and neutral loss scans in a triple quadrupole (QqQ) mass spectrometer has been used to identify and quantify changes in the abundances of glycerophospholipids extracted from retina and erythrocytes in a rat streptozotocin model of type 1 diabetes, 6 and 36 weeks after the induction of diabetes, compared with age-matched nondiabetic controls. The utility of an ''internal standard'' method compared with an ''internal standard free'' method for quantification of differences in the abundances of specific lipid ions was evaluated in both retina and erythrocyte lipid extracts. In retina, equivalent results were obtained by using the internal standard and internal standard free methods for quantification. In erythrocytes, the two methods of analysis yielded significantly different results, suggesting that factors intrinsic to particular sample types may influence the outcome of label-free lipidome quantification approaches.Overall increases (w25e35%) in the abundances of major retina glycerophospholipid classes were demonstrated in rats at 6 weeks of diabetes, relative to control animals. However, at 36 weeks of diabetes, subsequent overall decreases in retina glycerophosphatidylcholine (GPCho) and glycerophosphatidylethanolamine (GPEtn) abundances of 16% and 33%, respectively, were observed. Additionally, retina and erythrocyte GPCho lipids at both 6 and 36 weeks of diabetes exhibited increased incorporation of linoleic acid (18:2n6) and a decrease in docosahexaenoic acid (DHA (22:6n3) ) content. Finally, an approximately fivefold increase in the abundances of specific glycated GPEtn (Amadori-GPEtn) lipids were observed in the retina of 36-week diabetic rats, with a corresponding 1.6-fold increase of Amadori-GPEtn lipids in diabetic erythrocytes. (JALA 2009;14:383-99)